Most Popular
-
1
Actor Jung Woo-sung admits to being father of model Moon Ga-bi’s child
-
2
Wealthy parents ditch Korean passports to get kids into international school
-
3
Man convicted after binge eating to avoid military service
-
4
First snow to fall in Seoul on Wednesday
-
5
Industry experts predicts tough choices as NewJeans' ultimatum nears
-
6
Final push to forge UN treaty on plastic pollution set to begin in Busan
-
7
Nvidia CEO signals Samsung’s imminent shipment of AI chips
-
8
Korea to hold own memorial for forced labor victims, boycotting Japan’s
-
9
Opposition chief acquitted of instigating perjury
-
10
Job creation lowest on record among under-30s
[THE INVESTOR] South Korea‘s Celltrion Healthcare will ship 260 billion won (US$227.81 million) worth of a Remicade biosimilar developed by its affiliate Celltrion to the US by the end of 2016, the company said on Oct. 27.
Celltrion Healthcare, drug maker Celltrion’s overseas marketing affiliate, received a purchase order from US pharma giant Pfizer which holds exclusive rights to commercialize Celltrion’s autoimmune disease drug Inflectra, a biosimilar version of Johnson & Johnson’s Remicade, in select markets, including the US and Canada.
In other regions, the drug is sold under the name Remsima.
On Oct. 18, the two firms said they would begin selling the Remicade biosimilar in the US from late November.
According to the Korean company, total accumulated exports of Remsima have exceeded 1 trillion won this month.
It took four years for Celltrion to reach the figure since the pharmaceutical firm shipped the first batch of the rheumatoid arthritis treatment drug in 2012.
By Park Han-na (hnpark@heraldcorp.com)
Celltrion Healthcare, drug maker Celltrion’s overseas marketing affiliate, received a purchase order from US pharma giant Pfizer which holds exclusive rights to commercialize Celltrion’s autoimmune disease drug Inflectra, a biosimilar version of Johnson & Johnson’s Remicade, in select markets, including the US and Canada.
In other regions, the drug is sold under the name Remsima.
On Oct. 18, the two firms said they would begin selling the Remicade biosimilar in the US from late November.
According to the Korean company, total accumulated exports of Remsima have exceeded 1 trillion won this month.
It took four years for Celltrion to reach the figure since the pharmaceutical firm shipped the first batch of the rheumatoid arthritis treatment drug in 2012.
By Park Han-na (hnpark@heraldcorp.com)
